|
GSK submits Tyverb®/Tykerb® for first-line treatment of metastatic breast cancer in Europe, US
|
02 April 2009 |
|
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
|
20 February 2009 |
|
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899
|
10 February 2009 |
|
GSK to drive growth in emerging markets with acquisition of UCB products
|
27 January 2009 |
|
GlaxoSmithKline successfully completes tender offer for shares of Genelabs Technologies, Inc.
|
08 January 2009 |
|
GlaxoSmithKline to cease providing corporate political contributions
|
23 December 2008 |
|
GSK analysis shows Seretide/Advair is a well tolerated and effective medicine
|
08 December 2008 |
|
GSK and Neptunus form joint venture for the co-development of flu vaccines
|
24 November 2008 |
|
GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies
|
01 November 2008 |
|
GSKâs Emerging Markets strategy advances with acquisition in Egypt
|
20 October 2008 |